Compile Data Set for Download or QSAR
Report error Found 32 Enz. Inhib. hit(s) with all data for entry = 10168
TargetDihydrofolate reductase(Human pneumocystis pneumonia agent)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM18268(5-methyl-6-{[(3,4,5-trimethoxyphenyl)amino]methyl}...)
Affinity DataIC50: 2.10nMAssay Description:Table 7: The inhibitory activities of TMP and TMQ are listed for comparison. While the tested compounds displayed reduced potency against pjDHFR comp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetDihydrofolate reductase(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM18268(5-methyl-6-{[(3,4,5-trimethoxyphenyl)amino]methyl}...)
Affinity DataIC50: 2.60nMAssay Description:Table 7: The inhibitory activities of TMP and TMQ are listed for comparison. While the tested compounds displayed reduced potency against pjDHFR comp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetDihydrofolate reductase(Human pneumocystis pneumonia agent)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50332929(((2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-di...)
Affinity DataIC50: 120nMAssay Description:Table 7: The inhibitory activities of TMP and TMQ are listed for comparison. While the tested compounds displayed reduced potency against pjDHFR comp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetDihydrofolate reductase(Human pneumocystis pneumonia agent)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50461737(CHEMBL4227977 | US11111252, Compound 7 | US1100159...)
Affinity DataIC50: 160nMAssay Description:Table 7: The inhibitory activities of TMP and TMQ are listed for comparison. While the tested compounds displayed reduced potency against pjDHFR comp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetDihydrofolate reductase(Human pneumocystis pneumonia agent)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM497329(US11111252, Compound 2 | US11001595, Compound 3)
Affinity DataIC50: 177nMAssay Description:Table 7: The inhibitory activities of TMP and TMQ are listed for comparison. While the tested compounds displayed reduced potency against pjDHFR comp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetDihydrofolate reductase(Human pneumocystis pneumonia agent)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50461741(CHEMBL4227112 | US11111252, Compound 6 | US1100159...)
Affinity DataIC50: 210nMAssay Description:Table 7: The inhibitory activities of TMP and TMQ are listed for comparison. While the tested compounds displayed reduced potency against pjDHFR comp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetDihydrofolate reductase(Human pneumocystis pneumonia agent)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM497332(US11111252, Compound 3 | US11001595, Compound 4)
Affinity DataIC50: 213nMAssay Description:Table 7: The inhibitory activities of TMP and TMQ are listed for comparison. While the tested compounds displayed reduced potency against pjDHFR comp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM3032(CHEMBL29197 | N-(3-bromophenyl)-6,7-dimethoxyquina...)
Affinity DataIC50: 230nMAssay Description:Table 9: Compounds 1 and 2, Section D., (see FIG. 4, bottom row, far right column) each inhibit VEGFR-2 and PDGFR-β for antiangiogenic effects a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetDihydrofolate reductase(Human pneumocystis pneumonia agent)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM497336(US11111252, Compound 9 | US11001595, Compound 9)
Affinity DataIC50: 234nMAssay Description:Table 7: The inhibitory activities of TMP and TMQ are listed for comparison. While the tested compounds displayed reduced potency against pjDHFR comp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetDihydrofolate reductase(Human pneumocystis pneumonia agent)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM497329(US11111252, Compound 2 | US11001595, Compound 3)
Affinity DataIC50: 252nMAssay Description:Table 7: The inhibitory activities of TMP and TMQ are listed for comparison. While the tested compounds displayed reduced potency against pjDHFR comp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetDihydrofolate reductase(Human pneumocystis pneumonia agent)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM497327(US11111252, Compound 1 | US11001595, Compound 5 | ...)
Affinity DataIC50: 260nMAssay Description:Table 7: The inhibitory activities of TMP and TMQ are listed for comparison. While the tested compounds displayed reduced potency against pjDHFR comp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetDihydrofolate reductase(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM497329(US11111252, Compound 2 | US11001595, Compound 3)
Affinity DataIC50: 624nMAssay Description:Table 7: The inhibitory activities of TMP and TMQ are listed for comparison. While the tested compounds displayed reduced potency against pjDHFR comp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetDihydrofolate reductase(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM497327(US11111252, Compound 1 | US11001595, Compound 5 | ...)
Affinity DataIC50: 910nMAssay Description:Table 7: The inhibitory activities of TMP and TMQ are listed for comparison. While the tested compounds displayed reduced potency against pjDHFR comp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetDihydrofolate reductase(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM497332(US11111252, Compound 3 | US11001595, Compound 4)
Affinity DataIC50: 970nMAssay Description:Table 7: The inhibitory activities of TMP and TMQ are listed for comparison. While the tested compounds displayed reduced potency against pjDHFR comp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetDihydrofolate reductase(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM497336(US11111252, Compound 9 | US11001595, Compound 9)
Affinity DataIC50: 1.10E+3nMAssay Description:Table 7: The inhibitory activities of TMP and TMQ are listed for comparison. While the tested compounds displayed reduced potency against pjDHFR comp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetDihydrofolate reductase(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50461741(CHEMBL4227112 | US11111252, Compound 6 | US1100159...)
Affinity DataIC50: 1.40E+3nMAssay Description:Table 7: The inhibitory activities of TMP and TMQ are listed for comparison. While the tested compounds displayed reduced potency against pjDHFR comp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetDihydrofolate reductase(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM497329(US11111252, Compound 2 | US11001595, Compound 3)
Affinity DataIC50: 1.41E+3nMAssay Description:Table 7: The inhibitory activities of TMP and TMQ are listed for comparison. While the tested compounds displayed reduced potency against pjDHFR comp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetDihydrofolate reductase(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50461737(CHEMBL4227977 | US11111252, Compound 7 | US1100159...)
Affinity DataIC50: 1.90E+3nMAssay Description:Table 7: The inhibitory activities of TMP and TMQ are listed for comparison. While the tested compounds displayed reduced potency against pjDHFR comp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM497327(US11111252, Compound 1 | US11001595, Compound 5 | ...)
Affinity DataIC50: 2.80E+3nMAssay Description:Table 9: Compounds 1 and 2, Section D., (see FIG. 4, bottom row, far right column) each inhibit VEGFR-2 and PDGFR-β for antiangiogenic effects a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50111603(3-(4-(dimethylamino)benzylidene)indolin-2-one | 3-...)
Affinity DataIC50: 3.75E+3nMAssay Description:Table 9: Compounds 1 and 2, Section D., (see FIG. 4, bottom row, far right column) each inhibit VEGFR-2 and PDGFR-β for antiangiogenic effects a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetDihydrofolate reductase(Human pneumocystis pneumonia agent)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM497327(US11111252, Compound 1 | US11001595, Compound 5 | ...)
Affinity DataIC50: 3.90E+3nMAssay Description:Table 7: The inhibitory activities of TMP and TMQ are listed for comparison. While the tested compounds displayed reduced potency against pjDHFR comp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetDihydrofolate reductase(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM497327(US11111252, Compound 1 | US11001595, Compound 5 | ...)
Affinity DataIC50: 6.90E+3nMAssay Description:Table 7: The inhibitory activities of TMP and TMQ are listed for comparison. While the tested compounds displayed reduced potency against pjDHFR comp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM497329(US11111252, Compound 2 | US11001595, Compound 3)
Affinity DataIC50: 1.04E+4nMAssay Description:Table 9: Compounds 1 and 2, Section D., (see FIG. 4, bottom row, far right column) each inhibit VEGFR-2 and PDGFR-β for antiangiogenic effects a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM4810(cid_5329098 | CHEMBL276711 | SU5146 | (3Z)-3-[(3,5...)
Affinity DataIC50: 1.29E+4nMAssay Description:Table 9: Compounds 1 and 2, Section D., (see FIG. 4, bottom row, far right column) each inhibit VEGFR-2 and PDGFR-β for antiangiogenic effects a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 1(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM497346(US11111252, Compound CB67645 | US11001595, Compoun...)
Affinity DataIC50: 1.41E+4nMAssay Description:Table 9: Compounds 1 and 2, Section D., (see FIG. 4, bottom row, far right column) each inhibit VEGFR-2 and PDGFR-β for antiangiogenic effects a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM497327(US11111252, Compound 1 | US11001595, Compound 5 | ...)
Affinity DataIC50: 1.51E+4nMAssay Description:Table 9: Compounds 1 and 2, Section D., (see FIG. 4, bottom row, far right column) each inhibit VEGFR-2 and PDGFR-β for antiangiogenic effects a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM497327(US11111252, Compound 1 | US11001595, Compound 5 | ...)
Affinity DataIC50: 2.26E+4nMAssay Description:Table 9: Compounds 1 and 2, Section D., (see FIG. 4, bottom row, far right column) each inhibit VEGFR-2 and PDGFR-β for antiangiogenic effects a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetDihydrofolate reductase(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM50332929(((2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-di...)
Affinity DataIC50: 3.22E+4nMAssay Description:Table 7: The inhibitory activities of TMP and TMQ are listed for comparison. While the tested compounds displayed reduced potency against pjDHFR comp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM497329(US11111252, Compound 2 | US11001595, Compound 3)
Affinity DataIC50: 4.03E+4nMAssay Description:Table 9: Compounds 1 and 2, Section D., (see FIG. 4, bottom row, far right column) each inhibit VEGFR-2 and PDGFR-β for antiangiogenic effects a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM497329(US11111252, Compound 2 | US11001595, Compound 3)
Affinity DataIC50: 5.63E+4nMAssay Description:Table 9: Compounds 1 and 2, Section D., (see FIG. 4, bottom row, far right column) each inhibit VEGFR-2 and PDGFR-β for antiangiogenic effects a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 1(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM497327(US11111252, Compound 1 | US11001595, Compound 5 | ...)
Affinity DataIC50: 1.18E+5nMAssay Description:Table 9: Compounds 1 and 2, Section D., (see FIG. 4, bottom row, far right column) each inhibit VEGFR-2 and PDGFR-β for antiangiogenic effects a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 1(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM497329(US11111252, Compound 2 | US11001595, Compound 3)
Affinity DataIC50: 1.60E+5nMAssay Description:Table 9: Compounds 1 and 2, Section D., (see FIG. 4, bottom row, far right column) each inhibit VEGFR-2 and PDGFR-β for antiangiogenic effects a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2022
Entry Details
US Patent